Caravan Biologix, Inc. Collaborates with MDimune on Cell-Derived NanoVesicles for Cancer
15.9.2022 17:00:00 EEST | Business Wire | Press release
Caravan Biologix, Inc., a developer of novel cell-derived vesicle (CDV) therapeutics targeting specific cancers and gene therapy-related diseases, today announced that it has entered into an agreement with Seoul-based MDimune Inc. to apply their nanovesicle technology to enhance the effects of chimeric antigen receptor-expressing natural killer (CAR-NK) cells on various solid tumor cancers. Research findings should provide important insights as Caravan continues to advance the development of its proprietary Mini-CAR™ platform for stand-alone therapeutics and whole-cell CAR co-therapies.
“We are pleased to establish this collaboration with MDimune, a developer of bio-extrusion and delivery,” stated Tom Malcolm, Ph.D., CSO and Founder of Caravan Biologix. “Findings from this collaboration will support our mini- CAR-NK CDV program, which focuses on treating primary liver carcinomas and other human diseases.”
Seung Wook Oh, Ph.D., Chief Scientific Officer of MDimune added, “We are thrilled to launch this collaboration with Caravan Biologix. By joining the advanced mini-CAR-NK technology of Caravan and the enormous therapeutic potential of our vesicle technology, we hope to be able to demonstrate that our BioDrone® platform can significantly escalate the therapeutic promise of current CAR-T/NK-based therapies.”
“The signing of this agreement with Caravan Biologix is another important corporate milestone for MDimune. I am very pleased that our highly innovative and detail-oriented analytical approach to produce the highest quality of cell-derived vesicles at low cost has convinced Caravan Biologix to work with us on such an important endeavor to effectively treat patients with solid tumor cancers. It is clear that new solutions are needed to properly address the complexities associated with traditional whole cell CAR therapeutics,” stated Dr. Oh.
About MDimune Inc.
Founded in 2015, MDimune is dedicated to the development of a next-generation drug delivery platform known as BioDrone®. The company aims to provide a new and flexible modality to generate innovative therapeutics that can address the current challenges of cell & gene therapies. Based on cell-derived vesicles (CDVs) obtained from its proprietary extrusion technology, this novel class of drug carriers will enable highly effective drug delivery to various lesions and allow for treatment with minimum side effects and maximum efficacy. The BioDrone® platform technology is patented in the US, Europe, China, Japan, and Korea. BioDrone® Therapeutics Inc. was founded in 2019 in Seattle, WA to facilitate the global business development of BioDrone® platform technology.
About Caravan Biologix, Inc.
Caravan Biologix is a biotechnology company focused on creating novel therapeutic benefits to broad patient populations by addressing the limitations of whole cell chimeric receptor therapeutics. Caravan’s intellectual property protected technology enables it to develop a wide range of delivery and treatment options from gene editors to small molecules. Our allogeneic iPSC-derived mini-CAR™ and mini-VAN™ platforms, that are based on Cell-Derived Vesicles (CDVs), can be rapidly designed, engineered, and manufactured to build our internal pipeline as well as therapeutics for indications of interest to strategic partners. Caravan’s medicines are expected to show superior safety profiles including lower risk for cytokine release syndrome and other adverse immune reactions. Caravan’s approach will significantly reduce the complexity of manufacturing cell-based therapies, enhance blood-brain barrier penetration properties, and improve the targeted delivery of small molecules and other biologics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005157/en/
Contact information
For further information:
Caravan Biologix, Inc.:
Jeff Riley
CEO
+1.917.510.3773
jeff@caravanbio.com
MDimune Inc.
Seung Wook Oh, Ph.D.:
CSO
+82-2-2655-2636
swoh@mdimune.com; Info@biodroneus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
135 Global Thought Leaders, Decision-Makers and Experts to Speak at World Green Economy Summit 202630.9.2026 18:45:00 EEST | Press release
Under the patronage of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) and the World Green Economy Organization (WGEO) will organise the 12th World Green Economy Summit (WGES) on 21-22 October 2026 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930106199/en/ World Green Economy Summit 2025 (Photo: AETOSWire) Held under the theme ‘From Success to Scale: Showcasing the Green Economy’, the summit will host 135 speakers, including ministers, business leaders, government officials, decision-makers, experts and innovators from around the world. They will exchange insights and expertise while highlighting successful initiatives and models that can be scaled up to accelerate the transition to a green economy. “The World Green Economy Summit brings together gl
Boomi Recognized as a Leader in the 2026 Gartner® Magic Quadrant™ for API Management30.9.2026 18:30:00 EEST | Press release
Boomi, the data activation company for AI, today announced it has been recognized as a Leader in the 2026 Gartner® Magic Quadrant™ for API Management. We believe the recognition reflects Boomi’s sustained investment in Boomi API Management as the governance layer enterprises use to turn fragmented APIs into a trusted foundation for AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930240079/en/ Boomi Recognized as a Leader in the 2026 Gartner® Magic Quadrant™ for API Management Our Key Takeaways Boomi has been recognized as a Leader in the 2026 Gartner® Magic Quadrant™ for API Management. A complimentary copy of the report is available here. Boomi is also a Leader in the Gartner® Magic Quadrant™ for Integration Platform as a Service, where it has been named a Leader 12 consecutive times. Boomi API Management gives organizations one control plane for the full API lifecycle, with automatic discovery of APIs across distribu
Echodyne Awarded $250 Million JIATF-401 Counter-UAS Contract30.9.2026 18:00:00 EEST | Press release
Echodyne, the radar platform company, today announced an indefinite-delivery/indefinite-quantity (IDIQ) contract supporting the Joint Interagency Task Force 401’s (JIATF-401) Domestic Shield program. The agreement has a $250 million ceiling and an ordering period of up to 36 months, providing a path to acquire counter-unmanned aircraft system (C-UAS) capabilities for force protection, base defense and counter-drone operations in the United States and abroad. As part of the agreement, Echodyne’s advanced MESA radars will be available for procurement on JIATF-401’s C-UAS Marketplace for U.S. and Allied Nations. At the center of Echodyne’s radar portfolio is MESA, its software-defined metamaterials electronically scanned array architecture. MESA combines precise electronic beam steering with a compact, solid-state design, delivering high-fidelity radar data without the size, weight, power and cost traditionally associated with high-performance ESA radar. Its architecture supports continuo
AM Green Named Winner of Asian Lot in H2Global Auction Funded by German Government30.9.2026 17:46:00 EEST | Press release
AM Green Ammonia (India) Private Limited ("AM Green") has been selected as the sole winner of the Asian lot in the H2Global auction run by HINT.CO GmbH ("Hintco"), securing a long-term purchase agreement for the supply of Renewable Fuels of Non-Biological Origin (RFNBO) ammonia to Germany. The award follows a competitive bidding process in which AM Green’s offer was ranked first among the submissions received. Over a period of 10 years, Hintco will purchase ammonia from AM Green for a minimum value of EUR 585 million. Hintco may purchase additional quoted volumes from AM Green using proceeds generated from the resale of green ammonia in the European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930707955/en/ Left to right: Timo Bollerhey, CEO of Hintco and Co-Founder of H2Global, and Gautam Reddy, CEO of AM Green Ammonia, mark AM Green’s selection as the sole winner of the Asian lot in the H2Global auction for th
Tangent Robotics Raises 4.5M in Pre-seed Funding to Advance Fine Motor Skills for Robot Dexterity30.9.2026 17:23:00 EEST | Press release
In humans, fine motor skills can take two decades to fully develop. Tangent Robotics, which today announced its pre-seed funding round, aims to speed up the timeline for robots. The company will use the funds to develop skilled robotic manipulation capabilities at the intersection of hand hardware, touch sensing, and motor learning, and deploy them in demanding manufacturing environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930237631/en/ Tangent Robotics is developing fine motor skills for robot hands, which unlock the ability to perform critical tasks for what we want our economy to build locally, fast and at scale "Fine motor skills are hard to learn, and represent a layer that is currently missing in robotics but omnipresent in the real world," says Pedro Piacenza, Tangent's co-founder. "They unlock the ability to perform delicate, intricate manipulation. Tasks like assembly, threading, connector mating, gas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom